Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Cebon

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
British Journal of Cancer|April 29, 2016
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyS Bowyer, P Prithviraj, P Lorigan, et al.
Scientific Reports|July 26, 2018
Multiplex immunohistochemistry accurately defines the immune context of metastatic melanomaH Halse, A J Colebatch, P Petrone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-upR L Basser, L B To, J P Collins, et al.
British Journal of Cancer|September 6, 2006
Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotideJ Cebon, M Findlay, C Hargreaves, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 21, 2014
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trialA M Menzies, M T Ashworth, S Swann, et al.
Annals of Internal Medicine|October 1, 1994
Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trialD W Maher, G J Lieschke, M Green, et al.
Preparative Biochemistry & Biotechnology|May 11, 2005
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditionsR Murphy, S Green, G Ritter, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
British Journal of Cancer|April 29, 2016
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyS Bowyer, P Prithviraj, P Lorigan, et al.
Scientific Reports|July 26, 2018
Multiplex immunohistochemistry accurately defines the immune context of metastatic melanomaH Halse, A J Colebatch, P Petrone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-upR L Basser, L B To, J P Collins, et al.
British Journal of Cancer|September 6, 2006
Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotideJ Cebon, M Findlay, C Hargreaves, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 21, 2014
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trialA M Menzies, M T Ashworth, S Swann, et al.
Annals of Internal Medicine|October 1, 1994
Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trialD W Maher, G J Lieschke, M Green, et al.
Preparative Biochemistry & Biotechnology|May 11, 2005
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditionsR Murphy, S Green, G Ritter, et al.
Pageof 7